Liver Fibrosis Clinical Trials 2023

What are the top hospitals conducting liver fibrosis research?

In the battle against liver fibrosis, top hospitals across different parts of the United States are making significant strides through clinical trials. Located in Edinburg, Texas, the South Texas Research Institute is currently conducting three active trials focused on liver fibrosis. While they may have a smaller number of all-time trials at just three, their first recorded trial in 2020 demonstrates their commitment to exploring new treatments for this condition. Meanwhile, Massachusetts General Hospital in Boston has also dedicated its resources to liver fibrosis research with three ongoing trials and an impressive fifteen completed studies since their initial investigation back in 2000.

On the West Coast, the University of California San Francisco joins the ranks with three active clinical trials targeting liver fibrosis. Although they have conducted fewer all-time trials with a total of seven thus far, their trailblazing journey into understanding this disease began in 2013. Similarly, the University of Alabama at Birmingham is actively engaged in researching liver fibrosis through three ongoing clinical trials and five previously conducted studies since embarking on this path also in 2013.

Adding to these esteemed institutions' efforts is Hunter Holmes McGuire VA Medical Center situated in Richmond. This medical center boasts an extensive history when it comes to studying liver fibrosis; having commenced their first recorded trial as early as 2011 and accumulating an impressive nineteen all-time studies aimed at unraveling potential treatments for this condition.

These hospitals serve as beacons of hope for those affected by liver fibrosis, dedicating themselves to uncovering innovative therapies that can improve patients' lives. Through collaborative efforts nationwide within diverse locations such as Edinburg,Texas,Boston's Massachusetts General Hospital,and centers located from California's San Francisco Bay Area up until Birmingham or Virginia;a united front emerges towards achieving breakthroughs against Liver Fibriosis offering optimism not only for countless individuals directly impacted by this disease but also for shaping future medical advancements that could revolutionize patient care worldwide.

Which are the best cities for liver fibrosis clinical trials?

In the realm of liver fibrosis clinical trials, several cities emerge as prominent hubs for research and advancements. Seattle, Washington; New York, New York; Houston, Texas; Richmond, Virginia; and San Antonio, Texas are leading the way with a significant number of active trials focused on this condition. These trials explore various treatments such as belapectin, Fazirsiran, Atezolizumab, LPCN 1148, Resmetirom, Part B: Treatment Group 3 among others. With their extensive research initiatives and diverse range of investigative approaches to liver fibrosis treatment options these cities provide valuable opportunities for individuals seeking participation in cutting-edge clinical trials that could potentially shape future care strategies.

Which are the top treatments for liver fibrosis being explored in clinical trials?

Liver fibrosis, a serious condition with limited treatment options, is the focus of ongoing clinical trials exploring innovative approaches. One standout contender is prehabilitation, which has shown promise in two active liver fibrosis trials since its introduction in 2021. Another potential breakthrough is the Jumpstart Guide, currently being tested in one trial dedicated to liver fibrosis and first listed in 2023. With researchers diligently working towards new solutions, hope shines on the horizon for patients grappling with this challenging disease.

What are the most recent clinical trials for liver fibrosis?

Recent clinical trials for liver fibrosis offer promising prospects in the field of treatment. Intracavitary tocilizumab has emerged as a potential therapeutic approach, with phase 1 trials demonstrating its efficacy. Similarly, LY3885125 has shown promise in early-phase studies targeting liver fibrosis. Additionally, eHealth mindful movement and breathing group interventions have been explored to alleviate the impact of liver fibrosis on patients' well-being. The advancements made through these clinical trials bring hope to individuals affected by this condition, offering new possibilities for improved care and management strategies in the near future.

What liver fibrosis clinical trials were recently completed?

Several clinical trials focusing on liver fibrosis have recently achieved completion, marking significant progress in the search for effective treatments. In November 2021, Stanford University successfully concluded a trial investigating Empagliflozin 10 MG's potential to address this condition. Similarly, the University of Michigan completed a trial examining the effectiveness of Lactulose during the same month. Back in March 2021, Georgetown University finalized their study evaluating Proglumide's impact on liver fibrosis. These recent developments underscore researchers' commitment to combatting liver fibrosis and offer hope for patients grappling with this challenging condition.